Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. Sage Therapeutics, Inc.
CRL
•Sage Therapeutics, Inc.

Sage Therapeutics, Inc. – FDA CRL

Record Details

Agile Therapeutics, Inc. received a Complete Response Letter from the FDA regarding its New Drug Application (NDA 204017) for Twirla, a transdermal contraceptive system. The FDA's review, following the April 2012 NDA submission and subsequent amendments, determined the application could not be approved in its current form. The primary clinical concerns centered on inadequate evidence of efficacy. Two Phase 3 studies demonstrated unacceptably high Pearl Indices, significantly exceeding those of approved hormonal contraceptives. The agency noted substantial problems with study conduct, including low completion rates, poor subject follow-up, non-compliance with drug use and study procedures, and data quality issues, limiting confidence in the results. Product quality deficiencies were also identified across several areas. These included inadequate manufacturing controls and product specifications, insufficient justification for acceptance criteria, and issues with product labeling, specifically regarding strength identification. Further, impurities were not adequately characterized, the post-approval stability protocol needed updating, and a referenced Drug Master File was deemed inadequate. Discrepancies in manufacturing equipment used for clinical versus commercial production also required clarification. To address these concerns, Agile Therapeutics must conduct a new, rigorously overseen Phase 3 study demonstrating acceptable efficacy with the proposed to-be-marketed product, after resolving all product quality issues. This includes updating manufacturing controls, specifications, and labeling, fully characterizing impurities, ensuring the adequacy of the Drug Master File, and providing a comparison of manufacturing processes.

Company
Sage Therapeutics, Inc.
Product type
Drugs
Office
Division of Reproductive and Urologic Products
Person
  • Marie Foegh, M.D., Dr. Sc.
View Company Profile

ID · 6bc3ac1c-c25a-41cb-a4ae-83e2676097eb

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Sage Therapeutics, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.